Podcasts about rybelsus

Cet épisode est une présentation de Eros et Compagnie Code promo RAIS15 pour 15% de rabais⁠⁠⁠⁠⁠⁠https://www.erosetcompagnie.com/?code=rais15⁠⁠⁠⁠⁠⁠///ON A UN NOUVEL AMI YOUPPI YOUPPI!Épisode classique en mode trio cette semaine avec Julien Bernatchez, Murphy Cooper et Mathieu Niquette.Comme d'habitude, on dit bien de la sauce en intro: Murphy remercie Murphy, Niquette se rebaptise King Cringe, on reparle des sondes de Julien.On revient sur la domination du Des si et des rais verse dans le domaine de la publicité alors que Maxime, Linda et Niquette sont en grosse rotations dans les annonces de la télé québécoise. Et on en profite bien sûr pour taquiner Maxime sur son étrange et cryptique pub de Rybelsus. Murphy en profite pour annoncer qu'il joint lui aussi l'écurie de LOL LOL LOL, donc on le verra peut-être lui aussi prochainement au petit écran!Ensuite, dans les chroniques, Julien nous propose des diss-track à propos des autres podcasts et ça brasse en tabarouette! Puis Niquette nous révèle un pan de l'algorithme un peu brisé de la page Instagram de Des si et des rais!Et dans le segment Eros qui est pour le moins mémorable, Julien nous construit un ami qui pourra rester avec nous pour encore un bon moment!Des si et des rais: Quand personne ne veut jouer avec nous, on s'invente de nouveaux amis!Avec: Julien Bernatchez, Murphy Cooper et Mathieu NiquetteCaptation / Montage / Réalisation : Jonathan BarbeDate d'enregistrement: 12 avril 2025Date de diffusion: 15 mai 2025///Abonnez-vous à nos réseaux sociaux via le ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkTree⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Discord⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠SpeakPipe

Monde à Mario : Jachale et sa tourbe des états ! Julibou : Les pires « spotted » de ville ou municipalité Coup de 16h20 : On piège la fille du Air-Fryer pour une 3e fois avec les élections ! On joue à Cadeau d'hotesse et Choix de marde Révélations : Sa blonde a des tocs, comme tout le reste de l'équipe finalement

Semaglutide has become the weight management sensation of the decade, but what's the science behind the hype? In this episode, I break down how these GLP-1 agonists really work, why 85% of patients regain weight after stopping, and why I use them as just one tool in my comprehensive approach to metabolic health. From side effects to proper patient selection, get the unfiltered medical perspective you need before considering these medications. Episode Highlights: The meteoric rise of Ozempic, Wegovy and Rybelsus that's causing nationwide shortages How semaglutide actually works in your brain and digestive system to reduce appetite Why patients regain weight after stopping and the importance of lifestyle integration Real talk about side effects - from common digestive issues to rarer complications The critical shift needed in how medicine approaches obesity treatment Important differences between FDA-approved formulations and compounded alternatives My professional recommendations for patient selection and monitoring protocols How H.E.R. University supports comprehensive metabolic health beyond medication Episode Resources: Dr. Shawn Tassone's Practice | https://www.drshawntassone.com Dr. Shawn Tassone's Book | The Hormone Balance Bible Dr. Shawn Tassone's Integrative Hormonal Mapping System | Hormone Archetype Quiz Thank you to our sponsor, Endurance Products Company! After over 25 years of practicing medicine, I'll be the first to tell you that not all supplements are created equal. But when I discovered Dihydroberberine SR, by Endurance Products Company, I was genuinely impressed.  It's highly bioavailable and outperforms standard berberine at significantly lower doses. You can explore their offerings at endur.com. Not only is the science solid, but I love that Endurance Products Company is a family-run American company that has cared about doing things right since 1978. I've started recommending Dihydroberberine to my patients who struggle with blood sugar management, and the results speak for themselves. So much so, that I personally take this supplement for helping to support healthy blood sugar levels, heart health, and tap into how my body uses fats for energy As a special offer for my audience, Endurance Products Company is providing a 10% discount on your order! Simply use the code DRT10 at checkout when you visit endur.com. Medical Disclaimer This podcast and website represent the opinions of Dr. Shawn Tassone and his guests. The content here should not be taken as medical advice and is for informational purposes only. Because each person is so unique, please consult your health care professional for any medical questions.

Arecor Therapeutics CEO Sarah Howell talked with Proactive's Stephen Gunnion about the company's strong progress across its proprietary diabetes and obesity pipeline and partnerships. The discussion followed the release of Arecor Therapeutics' full-year 2024 results, where Howell detailed advances in AT278 — a highly concentrated, ultra-rapid acting insulin shown to be effective in patients with Type 2 diabetes and high BMI. AT278, according to Howell, delivers faster insulin onset and superior glucose control compared to current market alternatives. “We got more insulin on board faster,” she said, highlighting the product's pharmacokinetic and pharmacodynamic advantages. She added that the insulin is particularly suited for use in insulin pump therapies, especially for patients requiring high daily doses — a segment traditionally underserved by existing pump solutions. Beyond injectables, Arecor has entered the oral peptide delivery space with a new platform targeting enhanced bioavailability, initially focusing on oral GLP-1 for obesity. Howell noted, “We have overcome the first significant challenges of stabilising the peptide,” using the company's Arestat technology, with semaglutide development underway to improve upon existing oral GLP-1 drugs like Rybelsus. The company continues to expand its partner network and revenue-generating collaborations. It expects key data from oral peptide studies and a potential strategic partnership announcement for AT278 during 2025. For more insightful updates from biotech and pharma leaders, visit Proactive's YouTube channel. Don't forget to like this video, subscribe, and enable notifications to stay updated! #ArecorTherapeutics #AT278 #InsulinPump #GLP1 #DiabetesTreatment #ObesityDrugs #BiotechNews #PharmaInnovation #Semaglutide #OralDelivery #DrugDevelopment #ProactiveInvestors

Video Version Only on HCPLive! In this episode, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, explored two key trial updates in type 2 diabetes (T2D) care at the American College of Cardiology (ACC) 2025 Annual Scientific Sessions. SOUL Trial SOUL, a double-blind, placebo-controlled, event-driven trial, was designed to assess the cardiovascular effects of oral semaglutide (Rybelsus) in patients with T2D and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). A total of 9650 patients aged ≥50 years were enrolled across 450 centers in 44 countries. Analyses showed oral semaglutide (Rybelsus) was linked to a 14% reduction in major adverse cardiovascular events (MACE) in high-risk patients with T2D. This reduction included the incidence of cardiovascular (CV) death, myocardial infarction (MI), or stroke compared to placebo (HR, 0.86; 95% CI, 0.77 to 0.96; P = .006) over a median follow-up of 47.5 months. A 26% reduction in non-fatal MI was the primary driver of benefit, while safety findings identified gastrointestinal adverse events as more common with oral semaglutide. Based on these results, Novo Nordisk announced plans to pursue regulatory approval for a label expansion of oral semaglutide to include MACE risk reduction in adults with T2D and established CV disease. STRIDE Trial STRIDE, a double-blind, randomized, placebo-controlled trial initiated in 2020, assessed the effects of semaglutide 1.0 mg (Ozempic) on functional outcomes, including walking distance, in patients with T2D and peripheral artery disease (PAD). Conducted across 112 sites in 20 countries, the trial randomized 792 patients to receive semaglutide or placebo for 52 weeks. Analyses showed semaglutide use was associated with improvements in maximal walking distance, quality of life, and ankle-brachial index (ABI). SOUL met its primary endpoint, with semaglutide favoring the ratio from baseline in maximum walking distance at 52 weeks (1.21 [interquartile range, 0.95–1.55] vs 1.08 [0.86–1.36]), with an estimated treatment ratio (ETR) of 1.13 (95% CI, 1.06–1.21; P = .0004). At week 57, the improvement in walking distance was higher with semaglutide (ETR, 1.08; P = .038). Quality-of-life scores (VascuQoL-6) at week 52 were significantly higher in the semaglutide group (median difference, 1.00; P = .011), as were improvements in pain-free walking distance (ETR, 1.11; P = .0046). Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Editor's Note: In this episode, there was an error in the discussion about the new dosing for Rybelsus in the SOUL trial. The corrected information is that the 14 mg dose is now 9 mg with the new formulation, due to improved absorption. The full corrected statement is: “Instead of 3 mg, the new dose is 1.5 mg; instead of 7 mg, it's 4 mg; and instead of 14 mg, it's 9 mg.”

Subscriber-only episodeResources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55______________________________________________________________________Streamed live on Mar 26, 2025261 views • Streamed live on Mar 26, 2025Unlike traditional media, our live sessions offer raw, real-time discussions on obesity treatments. The community can engage directly in the comments, share their perspectives, and connect with experts and fellow patients. It's a space for honest dialogue, advocacy, and breaking the stigma around obesity, all while staying informed about the latest breakthroughs and understanding Mounjaro, Zepbound, Wegovy, Ozempic, Rybelsus, Saxenda, and Victoza and all the newest GLP1s.______________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy  Kim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

In this on-site episode of Don't Miss a Beat from the American College of Cardiology (ACC) 2025 Annual Scientific Sessions, hosts Muthiah Vaduganathan, MD, MPH, and Steve Greene, MD, break down a pair of trials from the meeting: STRIDE and SOUL. STRIDE Trial The STRIDE trial, funded by Novo Nordisk, was a double-blind, randomized, placebo-controlled study initiated in 2020 to evaluate the effects of semaglutide 1.0 mg (Ozempic) on walking distance in patients with type 2 diabetes (T2D) and peripheral artery disease (PAD). Conducted across 112 sites in 20 countries, the trial enrolled 792 patients, who were randomized 1:1 to receive semaglutide or placebo for 52 weeks. Participants assigned to semaglutide received an escalating dose regimen (0.25 mg to 1.0 mg). The primary endpoint, the ratio from baseline in maximum walking distance at 52 weeks, favored semaglutide (1.21 [interquartile range, 0.95–1.55] vs 1.08 [0.86–1.36]), with an estimated treatment ratio (ETR) of 1.13 (95% CI, 1.06–1.21; P = .0004). Secondary outcomes further supported semaglutide's benefit. At week 57, the improvement in walking distance was greater with semaglutide (ETR, 1.08; P = .038). Quality-of-life scores (VascuQoL-6) at week 52 were significantly higher in the semaglutide group (median difference, 1.00; P = .011). Pain-free walking distance also improved more with semaglutide than with placebo (ETR, 1.11; P = .0046). SOUL Trial The SOUL trial was a double-blind, placebo-controlled, event-driven study designed to assess the cardiovascular effects of oral semaglutide (Rybelsus) in patients with T2D and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). The trial enrolled 9650 patients aged ≥50 years and was conducted across 450 centers in 44 countries. Participants were randomized 1:1 to receive semaglutide or placebo, with a mean follow-up of 47.5 months. Primary outcome events occurred in 12.0% of participants receiving semaglutide (3.1 events per 100 person-years) compared with 13.8% in the placebo group (3.7 events per 100 person-years), resulting in a hazard ratio (HR) of 0.86 (95% CI, 0.77–0.96; P = .006). The primary driver of benefit was a 26% reduction in nonfatal myocardial infarction, with additional reductions in nonfatal stroke (12%) and cardiovascular death (7%). No significant improvements in kidney function were observed. Serious adverse events occurred slightly less frequently in the semaglutide group compared with placebo (47.9% vs 50.3%; P = .02). However, gastrointestinal adverse events, including nausea, diarrhea, constipation, and flatulence, were more common in the semaglutide group (5.0% vs 4.4%). Benefits were consistent across subgroups, including participants receiving sodium-glucose cotransporter-2 inhibitors. Relevant disclosures for Vaduganathan include Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others. Relevant disclosures for Greene include Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others. Chapters 00:00 - Intro 00:50 - STRIDE Background 02:50 - STRIDE Results 08:19 - SOUL Background 10:40 - SOUL Results

Subscriber-only episodeResources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55Sign The Petition for Avoidable Access to GLP-1s https://glp1collective.org/ ______________________________________________________________________We discuss Wegovy, Ozempic, Mounjaro, Zepbound, Rybelsus, Saxenda, and Victoza and the active ingredients Tirzepatide and Semaglutide. Unlike traditional media, our live sessions offer raw, real-time discussions on obesity treatments, where the community can engage directly in the comments, share their perspectives, and connect with experts and fellow patients. It's a space for honest dialogue, advocacy, and breaking the stigma around obesity, all while staying informed about the latest breakthroughs. Tonight, we are joined by @Downsidezed    / @thedownsized  ______________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF_____________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy  Kim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

Ozempic (semaglutida) es un medicamento para el control de la diabetes tipo 2 que se ha popularizado por sus efectos para bajar de peso. En este episodio explicaremos qué es la semaglutida, una clase de fármacos conocidos como agonistas de la hormona GLP-1, de la que se derivan medicamentos como Ozempic, Wegovy y Rybelsus. Hablaremos de sus beneficios, de sus efectos secundarios y de los retos en materia de salud pública relacionados con su consumo. Para este episodio entrevistamos a Carolina Solís Herrera, jefa de la División de Endocrinología en la Universidad de Texas en San Antonio, a Abril Campos Rivera, profesora investigadora del Institute for Obesity Research y la Escuela de Gobierno y Transformación Pública del Tec de Monterrey y a Paola Portillo Sánchez, médico internista y endocrinóloga de Tec Salud. Asimismo, recabamos los testimonios de tres usuarios de Ozempic. Si te interesa informarte más sobre este tema te invitamos a escuchar el Episodio 74: Fármacos para bajar de peso, ¿cuándo sí? También puedes leer: Fármacos como Ozempic para bajar de peso, ¿cuándo sí? Los medicamentos para la obesidad no son soluciones mágicas Encuentra más información en: TecScience.tec.mx La plataforma de divulgación del Tec de Monterrey. Y para que siempre estés al día con las últimas tendencias en investigación, suscríbete a nuestro newsletter.

On this episode of Fat Science, Dr. Emily Cooper, Andrea Taylor and Mark Wright delve deeper into the topic of compounded metabolic drugs. Dr. Cooper addresses criticisms from listeners about the previous discussion and provides insights into the economic reasons driving people towards compounded drugs. She also dissects the ethics and economics of the diet industry transforming into a subscription medicine model and the role of insurance in accessibility to metabolic treatments.Key Takeaways:Compounded drugs often act as a misleading alternative to brand medications, lacking FDA approval and potentially jeopardizing health outcomes.Employers significantly influence weight-related treatment coverage, and advocacy for coverage changes can be a crucial step towards accessible medications.Insurance restrictions and economic barriers force many to explore compounded drugs despite potential risks.The rise of online subscription models parallels the diet industry's modus operandi of exploiting vulnerable demographics for profit.Greater transparency and regulation within the pharmaceutical and insurance sectors are needed to ensure safe and equitable access to treatments.Personal Stories & Practical Advice:Andrea reflects on her decision to prioritize health despite the significant cost by sourcing medications through Canada rather than risking compounded drugs.Discussions emphasize the importance of a comprehensive and guided medical approach, advocating for patient education and active engagement with healthcare providers.Important Update: Changes in GLP-1 Medication Availability and Compounding RegulationsThis episode was recorded before recent regulatory developments regarding GLP-1 medications. As of our current information:The FDA has determined that shortages have been resolved for all formulations of tirzepatide (marketed as Mounjaro and Zepbound) and semaglutide (marketed as Rybelsus, Ozempic, and Wegovy). Consequently, compounding these medications is no longer legally permitted under FDA regulations.Additionally, Novo Nordisk has expanded its patient assistance program by implementing enhanced coupon discounts across all Wegovy dosage strengths to improve affordability and access to match Lilly's efforts for Mounjaro and Zepbound access.Please note that regulatory policies and manufacturer programs regarding these medications continue to evolve. For the most up-to-date information, we recommend consulting current FDA announcements and manufacturer websites.Resources:Connect with Dr. Emily Cooper on LinkedIn.Connect with Mark Wright on LinkedIn.Connect with Andrea Taylor on Instagram.Fat Science is a podcast on a mission to explain where our fat really comes from and why it won't go and stay away. We are committed to creating a world where people are empowered with accurate information about metabolism and recognize that fat isn't a failure. This podcast is for informational purposes only and is not intended to replace professional medical advice.If you have a question for Dr. Cooper, a show idea, feedback, or just want to connect, email us at info@diabesityinstitute.org.Fat Science is supported by the non-profit Diabesity Institute which is on a mission to increase access to effective, science-based medical care for those suffering from or at risk for diabesity. https://diabesityresearchfoundation.org/

Hoy en día podemos ver en los medios de comunicación como famosos de la talla de Elon Musk, Oprah Winfrey, Cristina aguilera, Kim kardashian, Luis Miguel, Lady Gaga y decenas de actrices de Hollywood, o ricos de Sillicon Valley… comentan que han perdido mucho peso y sin esfuerzo, gracias a un medicamento Unos hablan de ozempic, otros de wegoby y otros de mounjaro…. Otros comentan sus principios activos, liraglutida, semaglutida o tirzepatida Pero prácticamente nadie se ha parado a explicar los razonamientos fisiológicos que hay detrás de todo esto… Y para ello os traigo a Alfredo Andreu, farmacéutico , nutricionista y autor del libro, Ozempic & Co: Apagando el Ruido de la Comida, Perdiendo Peso y este es su web: https://www.habitonutricion.com/ Hablaremos de: Que es impacto tienen la insulina y el glucagón en la perdida de grasa y sensación de hambre y saciedad Que es el GLP 1 y que son los análogos de GLP 1 ) agonista del receptor del péptido similar al glucagón tipo 1 (GLP-1): Acciones en cerebro; hipotálamo nervio vago / pancreas: aumenta insulina y baja glucagón / tracto gastrointestinal vaciamiento gastrico tipos de medicamentos Agonistas duales GLP-1/GIP) Novo Nordisk: Produce Ozempic, Wegovy, Rybelsus, Victoza y Saxenda. Eli-Lilly: Trulicity y Mounjaro., Mounjaro es el primer agonista dual de GLP-1 y GIP, con potencial superior en la pérdida de pes Elimina grasa vs perder apetito…. Musculo y hueso Mi comparación : sueño y descanso ---- esteroides Efectos secundarios corto plazo (estomacales, Reducción de acetilcolina, lo que puede afectar la motilidad intestinal y la contracción muscular, hipoglucemias) medio plazo (posibilidad pancreatitis, cancer de tiroides…) largo plazo (rebote, perdida de masa muscular) Realmente quien debería ser candidato… ultima bala antes de operación en obesidad mórbida? Recuerda su web: https://www.habitonutricion.com/

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: New drug is looked at for T1D prevention, a new stem cell method is tested for beta cell transplanation without immunosuppresion drugs, the FDA okays the first fast-acting biosimilar insulin, Lilly lowers price of Zepbound, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX New research in type 1 diabetes prevention launches. Nektar Therapeutics and TrialNet will evaluate a drug currently used for exzema for patients with new onset stage 3 type 1 diabetes The drug is RezPeg – that's a shortened version of the name (rezpegaldesleukin)   This will be a study of about 70 adults and children and will launch this year. The new study will use a mixed meal tolerance test (MMTT) to measure the efficacy of rezpegaldesleukin or placebo for preserving C-peptide area under the curve over a 12-month duration comprised of a 6-month treatment period and a 6-month follow-up. Secondary objectives include pharmacokinetics, pharmacodynamics, and additional disease assessments including HbA1c levels and patient insulin requirements. Rezpegaldesleukin is being developed as a self-administered injection for a number of autoimmune and inflammatory diseases. https://www.prnewswire.com/news-releases/nektar-announces-clinical-trial-agreement-to-evaluate-rezpegaldesleukin-in-patients-with-new-onset-type-1-diabetes-mellitus-302383052.html XX NLS Pharmaceutics (NLSP) and Kadimastem announced successful completion of a pre-IND meeting with the FDA for iTOL-102, a potential diabetes treatment. iTOL-102 combines Kadimastem's IsletRx cells (stem cell-derived pancreatic islets) with iTolerance's immunomodulator iTOL-100, aiming to cure Type 1 Diabetes without requiring life-long immune suppression. The treatment was evaluated at the Diabetes Research Institute at the University of Miami School of Medicine, where it demonstrated functional insulin release and disease reversal in animal models. Based on FDA feedback, the companies are updating plans for safety toxicology studies and First-in-Human clinical trials. IsletRx is a clinical-grade product comprising human pancreatic islet-like cells capable of secreting insulin, offering a scalable source of insulin-producing cells to address donor islet shortages. The technology can detect glucose levels and produce required amounts of insulin and glucagon.   XX FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency has given a thumbs up to Sanofi's Merilog (insulin-aspart-szjj) as the first biosimilar to Novo Nordisk's NovoLog for patients with diabetes. Merilog will be provided by prefilled pen in a 3 mL dose or in a multiple-dose 10 mL vial. It is for adults and pediatric patients age 6 and older.     NovoLog and Novo Nordisk's other rapid-acting insulin follow-on Fiasp are among the drugs subject to government price negotiations under the Inflation Reduction Act. The new prices will be enacted at the start of next year. In July 2021, the FDA approved Biocon and Viatris' Semglee (insulin glargine-yfgn) as the first biosimilar to Lantus. Five months later, the U.S. regulator endorsed Eli Lilly's version of the drug, called Rezvoglar (insulin glargine-aglr). https://www.fiercepharma.com/pharma/fda-signs-sanofis-biosimilar-first-novo-nordisks-rapid-acting-novolog XX Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from cheap, compounded copies of weight loss medications. The company launched 7.5 mg and 10 mg vials of tirzepatide, sold under the brand name Zepbound, which typically cost $599 and $699, respectively. However, they are now available for $499 per month for patients paying without insurance. This applies to the first fill and all refills that are delivered every 45 days. Additionally, the company lowered the prices of the 2.5 mg and 5 mg vials to $349 and $499 per month, respectively. The company, which has seen a significant boost in profits from Zepbound and Mounjaro – essentially the same drug with different FDA-approved uses – announced that the new vials and pricing are exclusively available through the company's self-pay pharmacy, LillyDirect Self Pay Pharmacy Solutions. https://www.bloomberg.com/news/articles/2025-02-25/zepbound-cost-for-vials-cut-to-battle-cheaper-copycats XX Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a five-year period and could reach $102 billion next year, an analysis by Health and Human Services' inspector general found. The findings also come as the Trump administration weighs the fate of a Biden administration proposal that would require Medicare and Medicaid to cover GLP-1s for weight loss. The biggest spikes in usage were for Rybelsus, Novo Nordisk's once-daily GLP-1 tablet, and for the company's weekly injectable Ozempic, whose spending about doubled every year under review. https://www.axios.com/2025/02/25/medicare-spending-surge-diabetes-drugs XX Tandem Diabetes Care has secured a new FDA clearance for its insulin dose-calculating algorithm, opening up Control IQ for use in adults with Type 2 diabetes. The expanded label was based on data from a pivotal, randomized trial of more than 300 people with Type 2 diabetes, comparing its use to manual multiple daily injections. Tandem said it plans to present the study's results at the annual Advanced Technologies & Treatments for Diabetes meeting scheduled for next month in Amsterdam. https://www.fiercebiotech.com/medtech/tandem-diabetes-care-insulin-dosing-algorithm-nets-fda-clearance-type-2-diabetes XX Drugs approved for diabetes and obesity might be useful for the treatment of cognitive and mental health disorders, according to a new paper published in Nature Mental Health.   The study reviewed and integrated data from both preclinical and clinical studies to gather evidence on the possible effects of these drugs GLP1s and semaglutide  in conditions such as dementia, substance use disorders, psychotic disorders, mood and anxiety disorders, and eating disorders.     The study found promising but still preliminary evidence that GLP-1RAs could be beneficial over a range of cognitive and mental health disorders. These drugs have shown potential in improving cognition, reducing addictive behavior, and alleviating depression and anxiety. More data from robustly designed studies (i.e., randomized controlled trials) are needed to better understand GLP-1RAs' prospective efficacy and safety profile, especially with long-term use. https://medicalxpress.com/news/2025-02-diabetes-drugs-mental-health-treatment.html XX The FDA  issued draft guidance that includes recommendations to support the development and marketing of safe and effective AI-enabled The guidance, if finalized, would be the first guidance to provide comprehensive recommendations for AI-enabled devices throughout the total product lifecycle, providing developers with an accessible set of considerations that tie together design, development, maintenance, and documentation recommendations to help ensure the safety and effectiveness of AI-enabled devices. FDA is requesting public comment on this draft guidance by April 7. The agency also released draft guidance for the use of AI to support regulatory decision-making for drug and biological products. https://www.mddionline.com/artificial-intelligence/fda-issues-draft-guidance-for-ai-enabled-devices-seeks-public-feedback XX Congrats to Mila Clarke who some of you may know better as Hangry Woman on social. She has developed a great app called Glucose Guide and the Nutrition Assistant portion of that app went live this week. Glucose Guide is a web and mobile app that offers diabetes meal tracking, coaching, resources, recipes and community to those looking for help managing diabetes. MEAL AND BLOOD SUGAR TRACKING FEATURES.

In this enlightening episode of Healthy AF, Amy dives into the comprehensive world of GLP-1 RA drugs and their impact on weight loss. Whether you're contemplating starting a GLP-1 RA regimen or already on one and seeking more insight, this episode is packed with all the good information you need. Amy covers everything from the basics of GLP-1 RA drugs to the latest updates and data up to 2024. Discover practical advice on what additional health measures you can take while on these drugs to mitigate adverse effects and sustain weight loss. Tune in to arm yourself with knowledge and make informed decisions about your health journey with GLP-1 RA drugs. Trying to get healthy and stay healthy is f-ing hard! Everybody struggles with some aspect of it, no matter what they look like or what they tell you. There is no magic formula - a healthy lifestyle is a choice we need to make daily. Join Amy as she supports, informs, and entertains you on your journey toward health.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

GLP-1 agonists have taken the pharma world by storm, and Novo Nordisk has been at the forefront of it all with its blockbuster drug semaglutide, which it sells as Ozempic, Wegovy and Rybelsus. Semaglutide and other GLP-1s have gained widespread popularity as treatments for Type 2 diabetes and obesity, and it doesn’t stop there—they’re currently being tested in a wide variety of additional therapeutic areas and in new dosages and forms. In this week’s episode of “The Top Line,” Fierce’s James Waldron talked to Marcus Schindler, Novo’s chief scientific officer and executive VP of research and early development, about what’s next for GLP-1s and what else is top of mind at the Danish pharma. To learn more about the topics in this episode: Novo Nordisk hails ‘remarkable’ weight loss result for dual-acting oral drug in early trial Novo obesity prospect linked to ‘mild to moderate neuropsychiatric side effects’ in phase 2 Novo Nordisk axes once-monthly GLP-1/GIP agonist and MASH prospect Another day, another win for Novo in obesity, as early oral med appears to beat Wegovy See omnystudio.com/listener for privacy information.

Medications like Trulicity, Ozempic and Rybelsus help those with Type 2 diabetes manage their blood sugar levels. They're also being used for weight loss, and are believed to have other health benefits.

Discover how to get the BEST RESULTS out of Rybelsus! Watch Dr. Brian's tips on oral semaglutide usage as we cover key insights, common pitfalls, and strategies to optimize your treatment plan. For more information about this topic: https://brianyeungnd.com/2024/08/08/3-tips-to-best-use-rybelsus/ Get EXCLUSIVE content and SUPPORT us: https://ko-fi.com/brianyeungnd

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: World Diabetes Day roundup, existing drugs examined for T1D prevention, Blue Circle Health expands its novel T1D care model, Mounjaro studied further, Canada approves a new pumps system, and tragedy in the diabetes community.  Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Of course, World Diabetes Day was yesterday. November 14 marks the birthday of Sir Frederick Banting. who discovered insulin along with Charles Best in 1922. Lots of the tech companies are taking action.. I'm going to link up a great article highlighting what many of them are doing…. from Medtronics Blue Balloon challenge to Dexcom's Nick Jonas video and a lot more. https://www.drugdeliverybusiness.com/world-diabetes-day-2024/ XX A new triple combo therapy could restore insulin production in people with type 1 using existing medications. Levicure's triple-combo oral therapy is already considered very safe, because it involves two drugs approved by the U.S. Food and Drug Administration (FDA) and a well-known supplement. The therapy is a combination of: DPP4-inhibitors, a common type 2 diabetes medication Proton pump inhibitors (PPIs), a drug for severe acid reflux A proprietary version of gamma-aminobutyric acid (GABA), a supplement often used to treat anxiety Levicure says the combined effect can block beta cell destruction, suppress autoimmunity, and restore beta cell function. So far, Levicure's triple therapy has gone through only one retrospective chart review; it has not been put to the test in a randomized controlled trial https://www.diabetesdaily.com/blog/can-this-triple-combo-oral-therapy-restore-insulin-production-733261/   XX Blue Circle Health is expanding it's unique approach to type 1 care. Already active in Florida, Maine & Vermont, it will now be in Delaware and Ohio. Blue Circle Health is free and develops a personalized care plan for each participant, tailored to their unique needs, and offers comprehensive multidisciplinary support over a six-month period. It's paid for by the Helmsley Charitable Trust. The program is available to people 18 years of age and older that speak Spanish or English, regardless of insurance coverage or citizen status. We've got an upcoming podcast episode all about Blue Circle coming up soon. https://www.prnewswire.com/news-releases/blue-circle-health-expands-to-delaware-and-ohio-to-address-health-system-barriers-to-type-1-diabetes-care-and-education-302304170.html XX An international team of experts has created the world's first evidence-based guide for eating lower and low carb. The group says until now, people with type 1 diabetes and their healthcare providers have lacked comprehensive resources to help implement this approach safely and effectively. The guide provides essential information for dietitians and nutritionists and empowers them to work collaboratively with individuals and families who are interested in reducing carbohydrates. It's free and we've got the download link in the show notes. https://www.newswire.ca/news-releases/international-team-launches-first-guide-for-carbohydrate-reduction-in-type-1-diabetes-883729104.html XX A new pump system is available in Canada. mylife YpsoPump insulin pump and CamAPS FX hybrid closed-loop algorithm by Health Canada. mylife Loop consists of the mylife YpsoPump, a lightweight intuitive insulin pump, integrated with the CamAPS FX hybrid closed-loop, a mobile phone-based algorithm, and the Dexcom G6 Continuous Glucose Monitoring (CGM) System. Working together, these components provide an innovative, automated insulin delivery (AID) system designed to simplify insulin therapy and improve glycemic control for Canadians living with diabetes.   "The approval of the mylife YpsoPump and CamAPS FX marks an important milestone as we bring these advanced technologies to the Canadian market," said Sébastien Delarive, Chief Business Officer of Ypsomed Diabetes Care. "Although Ypsomed is relatively new in Canada, our established leadership in diabetes care throughout Europe provides a solid foundation for delivering innovative solutions to Canadians living with type 1 diabetes."   "We are excited to see both mylife YpsoPump and CamAPS FX approved," said Karina Schneider, General Manager at Ypsomed Canada. "This step brings us closer to offering an integrated solution that will help simplify diabetes management for Canadian patients, empowering them to take more control of their health." https://finance.yahoo.com/news/ypsomed-camdiab-receive-health-canada-205500840.html XX The FDA updates the labels for all GLP-1 receptor agonists with a warning about pulmonary aspiration during general anesthesia or deep sedation. The affected drugs are semaglutide (Ozempic, Rybelsus, Wegovy); liraglutide (Saxenda, Victoza); and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Mounjaro, Zepbound). the Medication Guide section of the label also has new additions. Patients are counseled to tell their healthcare provider if they are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). They are alerted that the GLP-1 RAs they are taking may cause serious side effects, including food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sedation. Patients are advised to tell all their healthcare providers that they are taking a GLP-1 RA before they are scheduled to have surgery or other procedures. https://www.medscape.com/viewarticle/fda-updates-glp-1-label-pulmonary-aspiration-warning-2024a1000k84?form=fpf XX Following an impressive data drop this summer highlighting the potential for Eli Lilly's tirzepatide to stave off progression to Type 2 diabetes in prediabetic patients, the Indianapolis-based drugmaker is laying out full results from its longest completed study of the dual GIP/GLP-1 receptor agonist to date. In the three-year SURMOUNT-1 trial, tirzepatide curbed the risk of disease progression to Type 2 diabetes by 94% versus placebo in adult prediabetes patients who were obese or overweight, Lilly said in a release Wednesday. The number represents a pooled result from three tirzepatide doses (5 mg, 10 mg and 15 mg) studied in the trial.   Putting those results into perspective, one new case of diabetes could be prevented for every nine patients treated with tirzepatide, which is marketed in the U.S. as Mounjaro for Type 2 diabetes and as Zepbound for obesity, Lilly said. https://www.fiercepharma.com/pharma/lilly-unwraps-detailed-data-showing-tirzepatide-kept-nearly-99-pre-diabetic-patients XX Edgparke commeical? XX https://www.bloomberg.com/news/articles/2024-10-25/apple-secretly-tests-blood-sugar-app-in-sign-of-health-ambitions XX XX And finally, many of you have likely already heard but we had some incredibly tragic news in the diabetes community, especially for the Breakthrough T1D ride community. I'm going to read from the Breakthrough T1D website: The leadership, staff, and volunteers of Breakthrough T1D mourn the tragic, sudden loss of five T1D Champions on Friday, Nov. 1, 2024.  Jeff and Michelle Bauer, Josh and Tammy Stahl and Barry Sievers were all killed in a singe car crash. The group included two married couples and one single individual—all very close friends and veteran Breakthrough T1D Ride participants. Of this incredibly impactful group, I knew Michelle Bauer personally, I met her as Michelle Alswager – you may know her as Jesse's mom. Her son, Jesse died from complications of type 1 in 2010. And that year, mile 23 on the JDRF ride was created as a mile of silence in memory of Jesse.  Now all riders are asked to ride in silence for that mile not only in memory of Jesse, but all those lost to type 1 diabetes. Michelle wrote her book, Jesse Was Here and created a program that's part of Beyond Type 1 to this day, all to help other families going through grief. She called me a few years ago when she was thinking of writing her book and I'm so grateful for our conversations and that our conversations may have helped her get it out there into a world where it's so needed. But we need Michelle here to talk about grief. More about talking to Michelle about the book).   Please, write the book, ride the bike, do the ironman, follow your heart and your dreams.  All of these incredible people gone too soon. https://www.breakthrought1d.org/news-and-updates/breakthrough-t1d-mourns-tragic-sudden-loss-of-five-ride-champions/   Thanks for joining me..

We're seeing a LOT more medications like Ozempic in the emergency department nowadays. In fact, 12% of U.S. adults have used a GLP-1 drug! So, what do we need to know about these drugs? Dr. Megan Boysen Osborn, Professor of Emergency Medicine at the University of California Irvine, discusses these GLP-1 agonists with host Maiya Smith.

In this episode of Hart2Heart with Dr. Mike Hart, Dr. Hart does a solo on GLP-1 agonists, especially Ozempic, and how they impact weight loss by reducing appetite and slowing gastric emptying. Originally designed for diabetes management, these drugs also help in lowering blood sugar levels. While many people have had success with weight loss, the host also discusses the challenges, such as side effects (nausea, gastrointestinal issues) and the potential return of cravings after stopping the medication. Dr. Hart stresses the importance of gradual dosing and mindful eating to sustain weight loss. Dr. Hart also touches on other GLP-1 drugs like Wegovy and oral forms like Rybelsus, comparing their effectiveness and applications. Show Notes: (0:00) Welcome back to the Hart2Heart Podcast with Dr. Mike Hart    (0:15) Dr. Hart is covering GLP-1 agonists and Ozempic (1:00) Understanding GLP-1 agonists (3:00) Different forms and dosages (10:00) Benefits and uses of GLP-1 agonists (11:30) Benefits beyond weight loss - cardiovascular health and neuroprotection (13:00) Common and serious side effects (17:03) How to avoid losing muscle mass (20:00) The deets on “Ozempic Face” (21:00) Mental state and cravings on Ozempic  (22:00) Managing cravings after stopping Ozempic (28:00) Cost considerations of GLP-1 agonists (29:30) Intro to Tirzepatide or Mounjaro  (31:30) Mechanisms and benefits of Tirzepatide (33:30) Clinical trials and side effects of Tirzepatide (36:00) Final thoughts and recommendations --- Dr. Mike Hart is a Cannabis Physician and Lifestyle Strategist. In April 2014, Dr. Hart became the first physician in London, Ontario to open a cannabis clinic. While Dr. Hart continues to treat patients at his clinic, his primary focus has shifted to correcting the medical cannabis educational gap that exists in the medical community.  Connect on social with Dr. Mike Hart: Social Links: Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart  

Last week, Gilead withdrew Trodelvy in bladder cancer after the antibody-drug conjugate failed to meet the primary endpoint in a confirmatory study. This follows Pfizer's recent withdrawal of another therapy that had earned FDA accelerated approval, Oxbryta for sickle cell disease. With few other options available to patients, BioSpace took a look at 5 sickle-cell candidates currently in clinical trials.   Following a disappointing Alzheimer's readout, the company's third neuro stumble in six months, Sage Therapeutics will lay off over 165 employees—about 33% of its workforce. The company is reporting Q3 earnings on Oct. 29.  On a more positive note, Vertex reported full Phase III data this week for its non-opioid pain treatment, su-zetri-gine. If approved, suzetrigine, which has a PDUFA date of Jan. 30, 2025, would be the first new class of acute pain medicine in more than two decades. And on Monday, a company that never leaves the news, Novo Nordisk, announced positive results from a cardiovascular study with its oral version of semaglutide, Rybelsus. In other Novo news, scrutiny around Novo Holdings' acquisition of Catalent is heating up with a coalition of unions, consumer groups and public interest organizations last week expressing their concerns about the buyout. This prompted BioSpace to unpack the unique structure of the collection of organizations that is Novo. Finally, Sanofi is having a busy month, securing the sale of its healthcare unit Opella and separately paying approximately $326 million to obtain a 16% stake in European radiopharma biotech Orano Med. Radiopharma is skyrocketing in popularity, and some companies are even trying to marry it with another hot therapeutic spaces: antibody-drug conjugates. Could radiolabeled ADCs overcome some of the side effects of radiation treatments, speed up treatment times and enable lower doses than traditional therapies?

Amy's on a new Bravo lesbian tv show, Ryan's hair is old and brittle, baby shower etiquette, Riley- Ruler of Elves, Sabrina Carpenter, we dissect the Rybelsus commercial, Amy's new obsession is ‘Nobody Wants This', Ryan zooms with a couple in bed, Amy goes camping with her Dad, we chat fish from other planets, Ryan farts on a second date, Amy has an intimate experience at Jewel Lake, a listener PLT story about a nice viking wedding, Lil Donna is back with a European PLT story and we play Rupaul Song Or Not! Hosted on Acast. See acast.com/privacy for more information.

Nutritionist Leyla Muedin discusses the popular pharmaceutical semaglutides, including Ozempic, Wegovy, and Rybelsus. She explains their mechanisms of action, uses, and common side effects. Leyla also introduces Calocurb, a natural alternative made from hops, and explains how it can mimic the effects of semaglutides by stimulating the release of crucial digestive hormones. Throughout the episode, she emphasizes the importance of a balanced diet rich in fats and proteins for optimal health and weight management.

Companies are spending big bucks advertising weight-loss drugs like Ozempic and Rybelsus. This week, we're dropping an episode of Brian Goldman's White Coat, Black Art podcast into our feed.We thought you might find the topic interesting. In Canada, "reminder ads" can only give the medication's name, but they can't tell you what the drug is for. They just tell people to ask their doctor for more information. I join Dr. Goldman in this episode to talk about those ads.Are those ads good – or are they bad? Hosted on Acast. See acast.com/privacy for more information.

Companies are spending big bucks advertising weight-loss drugs like Rybelsus and Ozempic. But in Canada, "reminder ads" can give only the medication's name, not what it's for, telling people to ask their doctor for more. Special guest Terry O'Reilly, host of CBC's Under the Influence, says it can result in bad ads that turn people off, while pharmaceutical policy expert Barbara Mintzes says reminder ads can do more harm than good.

It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: Dexcom CGM is worn in space, two over-the-counter CGMs are now available, a large new study looks at potential dietary causes of type 1, and researchers are looking at a gel version of GLP-1 medications. Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Astronauts on the Polaris-Dawn mission are wearing the Dexcom G6 CGM. Polaris Dawn launched this week with astronauts wearing the G6 to better understand the effects of spaceflight on human health. The crew intends to conduct research to advance human health on Earth and the understanding of health during long-duration spaceflights. “This health research-driven mission marks another first for Dexcom, with our industry-leading CGMs being worn by astronauts in outer space,” said Jake Leach, EVP and COO at Dexcom. “We are thrilled to play a role in building a future where people with diabetes are empowered to accomplish anything they set their minds to–including the possibility of exploring outer space–without being held back by their condition.” Over five days in space, the Polaris Dawn crew plans to conduct around 40 scientific experiments. That includes several aimed at better understanding the effects of spaceflight on glucose health. Labront, a platform assisting health researchers in collecting and analyzing physiological data, is collaborating with Dexcom. It plans to provide advanced analytics for the data collected by the crew.   According to a news release, the mission expects to explore how microgravity, fluid shifts, and blood flow restriction exercises impact glucose regulation. https://www.drugdeliverybusiness.com/dexcom-cgm-outer-space-polaris-dawn/ XX There are now two OTC CGMs.. Dexcom launched Stelo a few weeks ago and now Abbott says Lingo is for sale. They're both available on the companies' websites, cost about the same, but you can opt to buy only one Lingo where Stelo comes in pairs. Lingo is meant for people without diabetes – it's a health bio sensor. Abbott has another CGM called Libre Rio meant for people with type 2 who don't take insulin. Not a lot of details about what the real difference are here – likely just in the software – No word on when Rio will be available. https://www.cnbc.com/2024/09/05/-abbott-launches-its-first-over-the-counter-continuous-glucose-monitor-in-the-us.html XX Warning about flying with an insulin pump – And I want to be clear here because I'm sure you'll see some scary headlines. This is really about pressure emergencies in planes. For the study, researchers tested 26 insulin pumps in a hypobaric chamber programmed to mimic the atmospheric changes during a normal commercial airline flight. “The drop in cabin pressure during ascent may lead to a slight increase in insulin delivery as a result of the formation of air bubbles which displace excess insulin out of the cartridge,” Fan said in a meeting news release. “A slight reduction in insulin delivery is also possible during descent as the increasing air pressure dissolves the air bubbles, sucking insulin back into the pump.” People on insulin pumps could be in real trouble in the event of rapid decompression of the cabin at altitude, researchers said. In that case, the pumps could deliver an insulin overdose -- dropping blood sugar levels so much that there's a significant risk of hypoglycemia, results show. These researchers recommend disconnecting and reconnect at take off and landing, but that's not going to help if there is emergency rapid decompression. As always, be prepared with emergency glucagon and low snacks and supplies. https://www.healthday.com/health-news/diabetes/flying-could-upset-insulin-pump-function-for-type-1-diabetics XX Lilly moves forward with it's version of once weekly basal insulin. Clinical trials show it can help control both Type 1 and Type 2 diabetes as well as daily basal injections do. However, in those with type 1 diabetes, there was an increased risk for hypoglycemia.  This is the same issue with Novo Nordisk's Awiqli insulin – approved in Canada but not in the United States. https://www.upi.com/Health_News/2024/09/11/weekly-insulin-injections-effective-diabetes-weekly/8711726068680/ https://www.medscape.com/viewarticle/once-weekly-insulin-looks-good-t2d-risk-seen-t1d-2024a1000gh8 XX Eating what seems like really healthy foods could be associated with a higher risk of developing type 1 diabetes. New study shows that eating fruit, oats and rye in childhood is associated with a higher risk of developing type 1 diabetes (T1D). Eating berries, however, is linked to lower odds of developing the condition. What triggers the immune system's attack is unknown but is thought to involve a combination of a genetic predisposition and an environmental trigger such as a virus or foodstuff. T1D, the most common form of diabetes in children, is increasing worldwide. The number of cases worldwide is projected to double in just 20 years, from 8.4 million in 2021 to 17.4 million by 2040. Finland has the highest incidence of T1D globally, with 52.2 cases per 100,000 children under the age of 15 – more than five times higher than in the 1950s. 5,674 children (3,010 boys and 2,664 girls) with genetic susceptibility to T1D were followed from birth to the age of six. Food records completed by their parents repeatedly from the age of three months to 6 years provided information on the entire diet.   The 34 food groups covered the entire diet and, when they were all factored in, several foods were associated with a higher risk of developing T1D.   To the best of our knowledge, this is the first time a child's entire diet has been considered at the same time." The results show that the more fruit, oats or rye children ate, the more their risk of T1D increased. In contrast, eating strawberries, blueberries, lingonberries, raspberries, blackcurrants and other berries appeared to provide protection against T1D. The more berries a child ate, the less likely they were to develop T1D. Oats, bananas, fermented dairy products (such as yogurts) and wheat were associated with an increased risk of islet autoimmunity, whereas cruciferous vegetables, such as broccoli, cauliflower and cabbage, were associated with decreased risk. It is, however, too early to make any dietary recommendations. The researchers are quick to point out that they don't really know the “why” here. Could be the food itself, could be pesticides, and until the results are replicated they urge parents not to change their child's diet. https://www.news-medical.net/news/20240909/Eating-fruit-oats-and-rye-in-childhood-may-increase-type-1-diabetes-risk.aspx XX Researchers in France have developed a once-a-month hydrogel-based delivery system for semaglutide, significantly simplifying diabetes and weight management Semaglutide, marketed as Ozempic, Rybelsus, and Wegovy, is a GLP-1 receptor agonist that helps to regulate blood sugar levels and promote weight loss. This medication is especially effective in managing type 2 diabetes and is available in both injectable and oral forms. Semaglutide enhances the body's natural ability to control blood glucose and reduce appetite, providing a dual approach to treatment.     The new hydrogel delivery platform uses two innovative degradable polymers that are chemically bound to one another to form a gel, but allow slow, sustained release of soluble peptides over 1 to 3 months. How do you slow release a gel? With an injection. It goes under the skin. This is still in animal studies, so we're a ways off from human clinical trials. https://scitechdaily.com/new-semaglutide-hydrogel-say-goodbye-to-weekly-shots-for-diabetes-and-weight-loss/ XX   Edgepark Commercial XX   Embecta has received clearance from the Food and Drug Administration for its first insulin patch pump. The device can be used by people with Type 1 or Type 2 diabetes and worn for up to three days. It includes a 300-unit insulin reservoir. Embecta said Tuesday it plans to develop a closed-loop version of the pump for automated insulin dosing that it will submit to the FDA in the future using the Tidepool Loop algorithm. Earlier this summer, Insulet received FDA clearance to offer its Omnipod 5 pump to people with Type 2 diabetes. Diabetes tech firms have focused on Type 2 in recent years as insurance coverage improves. https://www.medtechdive.com/news/embecta-gets-fda-nod-for-insulin-patch-pump/725904/ XX An artificial intelligence (AI)–driven voice algorithm showed "excellent agreement" with the American Diabetes Association (ADA) risk test in detecting adults with type 2 diabetes (T2D), research presented at the European Association for the Study of Diabetes (EASD) 2024 Annual Meeting revealed.   The AI model detected T2D with 66% accuracy among women and 71% in men, and there was 93% agreement with the questionnaire-based ADA risk score, demonstrating comparable performance between voice analysis and an accepted screening tool.   The Colive Voice project includes volunteers from all over the world; however, the current study was restricted to adults from the United States, both with and without T2D, "This first proof of concept was limited to English speakers, and further research will need to enroll more diverse populations, in terms of languages and sociodemographic background," he said. "This study represents a first step toward using voice analysis as a first-line, highly scalable T2D screening strategy," the authors concluded. "The next studies will have to demonstrate the robustness of our approach in diverse populations and also include people living with prediabetes," Fagherazzi said. "If proven reliable, we expect such technology to be available in the next 5-10 years. Then, it could be deployed easily at scale in millions of smartphones worldwide and reduce undiagnosed diabetes cases." https://www.medscape.com/viewarticle/ai-voice-analysis-diabetes-screening-shows-promise-2024a1000ggw XX Join us again soon!

This week, we have three compelling research papers that are sure to expand your clinical acumen. STUDY #1: We explore the debate surrounding the new PREVENT calculator's impact on predictions of 10-year risk for atherosclerotic cardiovascular disease and statin eligibility. Will the current guidelines from the American Heart Association and American College of Cardiology remain the gold standard, or are we on the cusp of a significant paradigm shift?  Diao, JA, Shi, I, Murthy, VL, et al. 2024. Projected changes in statin and antihypertensive therapy eligibility with the AHA PREVENT cardiovascular risk equations. JAMA. Published online. (https://doi.org/10.1001/jama.2024.12537) Grant, JK, Ndumele, CE, and Martin, SS. 2024. The evolving landscape of cardiovascular risk assessment. JAMA. Published online. (https://doi.org/10.1001/jama.2024.13247) Khan SS, and Lloyd-Jones, DM. 2024. Statins for primary prevention of cardiovascular disease — With PREVENT, what's a clinician to do? JAMA. Published online. (https://doi.org/10.1001/jama.2024.13887) Khan, SS, Matsushita, K, Sang, Y, et al. 2023. Development and Validation of the American Heart Association's PREVENT Equations. J Circulation. 6: 430-449. (https://doi.org/10.1161/CIRCULATIONAHA.123.067626) STUDY #2: Next, we dive into a great study examining the connection between antihypertensive medications and eczematous dermatitis in older adults. This extensive population-based research offers great insights that could change your approach to managing hypertension in patients with dermatologic concerns. Could your favorite antihypertensive medication be the culprit behind your patient's new skin condition? Ye, M, Chan, LN, Douglas, I, et al. 2024. Antihypertensive medications and eczematous dermatitis in older adults. JAMA Dermatol. Published online. (https://doi.org/10.1001/jamadermatol.2024.1230) Joly, P, Benoit-Corven, C, Baricault, S, et al. Sophie Baricault. 2007. Chronic Eczematous Eruptions of the Elderly Are Associated with Chronic Exposure to Calcium Channel Blockers: Results from a Case–Control Study. J Invest Derm. 12: 2766-2771. (https://doi.org/10.1038/sj.jid.5701018) Summers, EM, Bingham, CS, Dahle, KW, et al. 2013. Chronic Eczematous Eruptions in the Aging Further Support for an Association With Exposure to Calcium Channel Blocker. JAMA Dermatol. 7: 814-818. doi:10.1001/jamadermatol.2013.511 STUDY #3: Finally, we dissect a hotly discussed study linking semaglutide with non-arteritic anterior ischemic optic neuropathy. Garnering attention both in academia and the lay media, this study's robust methodology lends significant weight to its findings. But does this potential risk necessitate altering prescribing habits for semaglutide? Hathaway, JT, Shah, MP, Hathaway, DB, et al. 2024. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024. Published online. (https://doi.org/10.1001/jamaophthalmol.2024.2296) Join us for a closer look at these pivotal studies. It's a conversation you won't want to miss.  Learn more with Medmastery's courses: Hypertension Mini (1 CME) Get a Basic or Pro account, or, get a Trial account. Show notes: Visit us at  https://www.medmastery.com/podcasts/cardiology-podcast.

SummaryIn this conversation, Jason and Mindy discuss various topics including trouble sleeping, weight loss drugs, online trolling, different types of naps, and what their friends and family would assume they had done if they were arrested. They also share an inspirational quote and mention their upcoming merchandise on their website.https://www.lowtreestudios.com/https://www.youtube.com/@lowtreestudiosWeight-loss drugs are taking a big bite out of the food business. People taking meds such as Ozempic, Rybelsus and Wegovy — originally developed to treat diabetes — spend less on groceries and have healthier choices in their basket, according to a new study on shopping behaviors. Analytics firm Grocery Doppio found that semaglutide-takers purchase 47% fewer baked goods; 28% less soda and sugary beverages; 17% less booze; and 13% less processed foods. On the other hand, they are buying more healthy foods, thanks reduced appetites and changes to their taste buds. A new study published in Behavioral Sciences determined that those with dark humor are more likely to engage in online trolling. And what's more, they don't appreciate it when their antagonism turned back on them. In other words, trolls don't like being trolled. Online trolling is a social behavior characterized by deception and disruption. A troll tries to incite controversy simply to watch people turn against each other. And now, the doozy: The researchers' findings also indicate that people who possess a dark sense of humor are more likely to demonstrate sadism and Machiavellianism (being cunning, scheming, and unscrupulous).NAP RAPPIN':It's Tuesday. Maybe you were up late watching Olympics or your favorite show. Sounds like a good excuse for a nice nap, right after work. Here are 4 types of naps, and how to choose which one is perfect for you…“Power Nap.” For most, a classic “power nap” of 10-20 minutes in the early afternoon will help them shake off that post-lunch blahs, and feel OK for the rest of the day. This is great if you often feel lethargic for a few hours in the afternoon.“Coffee Nap”: If a short nap isn't much help, try this. Drink a cup of coffee quickly, then lie down. It takes caffeine about 10 minutes to affect you, and about 45 minutes to reach peak concentration in your blood. That means you can get a power nap in, then wake up just as the caffeine hits, giving you an amplified sense of sharpness and clarity. “Convenient Nap”: Scheduling a nap is great, but what if your schedule is all over the place? An imperfect nap is better than no nap at all. Nap when the baby is sleeping, while on public transit, or during your lunch hour. “Performance Nap”: If you have a stressful or physically demanding task coming up, such as a presentation or a marathon, a short nap a few hours ahead of time can definitely boost your performance.

We sit down with Jennifer Jonsson, a patient advocate, to explore the complex world of medication interactions and their impact on mental health. Jennifer shares her personal journey of managing ADHD, bipolar disorder, and Type 2 diabetes while navigating the unexpected side effects of medications like Rybelsus. We discuss the importance of self-advocacy, effective communication with health care providers, and practical strategies for handling multiple chronic conditions. Jennifer Jonsson is a patient advocate. She discusses the KevinMD article, "Can weight loss medication interfere with ADHD meds?" Our presenting sponsor is Nuance, a Microsoft company. Together, Microsoft and Nuance are leveraging their rich digital technology and advanced AI capabilities to tackle some of health care's biggest challenges. AI-driven technology promises to revolutionize patient and provider experiences with clinical documentation that writes itself. The Nuance Dragon Ambient eXperience, or DAX for short, is a voice-enabled solution that automatically captures patient encounters securely and accurately at the point of care. DAX Copilot combines proven conversational and ambient AI with the most advanced generative AI in a mobile application that integrates directly with your existing workflows. Physicians who use DAX have reported a 50 percent decrease in documentation time and a 70 percent reduction in feelings of burnout, and 85 percent of patients say their physician is more personable and conversational. Discover AI-powered clinical documentation that writes itself. Visit https://nuance.com/daxinaction to see a 12-minute DAX Copilot demo. VISIT SPONSOR → https://nuance.com/daxinaction SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended GET CME FOR THIS EPISODE → https://www.kevinmd.com/cme I'm partnering with Learner+ to offer clinicians access to an AI-powered reflective portfolio that rewards CME/CE credits from meaningful reflections. Find out more: https://www.kevinmd.com/learnerplus

A class of medications known as GLP-1 receptor agonists has revolutionized the treatment of type 2 diabetes and obesity. These drugs mimic the action of glucagon-like peptide-1 (GLP-1), a hormone that stimulates insulin secretion and inhibits glucagon release, helping to regulate blood sugar levels and promote weight loss. In this podcast, we'll talk about the differences among some of the most well-known GLP-1 receptor agonists for type 2 diabetes. Ozempic (Semaglutide) Form: Injectable Dosing Frequency: Once weekly Uses: Primarily for type 2 diabetes (lower blood sugar and A1c); also approved for reducing the risk of major cardiovascular events like heart attack and stroke in adults with type 2 diabetes and known heart disease. Keep in mind, Wegovy (semaglutide) is a higher-dose version that's approved for weight loss. When you start taking Wegovy or Ozempic, you'll begin with a low dosage. Your prescriber will increase your dosage every four weeks until you reach the target amount. However, the specific dosage you inject will differ depending on the medication. The maximum dose for Ozempic is 2mg weekly, while the target dose for Wegovy is 2.4mg weekly. Rybelsus (Semaglutide) Form: Oral tablet Dosing Frequency: Once daily Uses: Lower blood sugar and A1c in people with type 2 diabetes. Rybelsus shares the same active ingredient as the injectable medications Ozempic and Wegovy. Ozempic is also approved for Type 2 diabetes, while Wegovy is approved specifically for weight loss. Rybelsus is available in three different strengths: 3 mg, 7 mg, and 14 mg. Similar to Ozempic, the dose is slowly increased every 4 weeks.  Good to know: It's important to take Rybelsus first thing in the morning with 4 oz of water. After taking it, you should wait at least 30 minutes before eating, drinking, or taking other medications. Failing to do so may reduce its effectiveness. Currently, Rybelsus is undergoing clinical trials to evaluate its effectiveness for weight loss. The trials involve higher doses than those approved for diabetes treatment. Results indicate that a 50 mg dose of oral semaglutide (Rybelsus) achieves weight loss comparable to Wegovy.  Trulicity (Dulaglutide) Form: Injectable Dosing Frequency: Once weekly Uses: Type 2 diabetes; and like Ozempic, it's also approved for reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Like Ozempic and Rybelsus, you will start at a low dose to help reduce side effects. Your healthcare provider will then gradually increase the dose, balancing the management of side effects with the benefits of blood sugar control. The maximum dose for Trulicity is 4.5mg weekly. Victoza (Liraglutide) Form: Injectable Dosing Frequency: Once daily Uses: Type 2 diabetes; also approved to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Victoza is one of three GLP-1 agonists approved for treating Type 2 diabetes in children aged 10 and older. The other options are Trulicity (dulaglutide) and Bydureon BCise (exenatide). More on this later. Ozempic, however, is only approved for use in adults. Saxenda and Victoza are both injectable medications containing liraglutide, but they are approved for different uses. Saxenda is FDA-approved for chronic weight management in people 12 and older, while Victoza is approved for treating Type 2 diabetes in people 10 and older. Victoza also helps lower the risk of major adverse cardiovascular events in adults with diabetes and heart disease. Both medications are injected once a day, starting with a low dose that is gradually increased over time. The target dose for Saxenda is 3 mg once daily, whereas the maximum dose for Victoza is 1.8 mg once daily. Byetta (Exenatide) Form: Injectable Dosing Frequency: Twice daily Uses: Type 2 diabetes. Additional Benefits: It has a shorter duration of action than other GLP-1 agonists, which may be preferable for some patients. Byetta, approved in 2005, was the first GLP-1 medication of its kind for diabetes. Its active ingredient, exenatide, is a synthetic version of a substance found in Gila monster saliva.  The recommended starting dose for Byetta is 5 mcg twice daily, administered within 60 minutes before your morning and evening meals. After one month, your healthcare provider may increase the dose to 10 mcg twice daily. Starting at a lower dose helps reduce stomach-related side effects. Bydureon BCise (Exenatide Extended-Release) Form: Injectable Dosing Frequency: Once weekly Uses: Type 2 diabetes. Additional Benefits: Extended-release formulation provides a more convenient dosing schedule compared to Byetta. Unlike Byetta, Bydureon BCise has a fixed dose of 2 mg administered once weekly, on the same day each week. It can be taken at any time of day, with or without food. Mounjaro (Tirzepatide) Form: Injectable Dosing Frequency: Once weekly Uses: Type 2 diabetes. Additional Benefits: Dual action as it targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, potentially offering enhanced efficacy in blood sugar control. Mounjaro is not approved for weight loss; however, its active ingredient, tirzepatide, is approved for weight loss under the brand name Zepbound. Typically, Mounjaro's starting dose is 2.5 mg once weekly for four weeks. By week 5, the dosage is often increased to 5 mg once weekly for another four weeks. Following week 9, if necessary for better blood sugar management, the dosage can be escalated to 7.5 mg weekly. It's important not to increase Mounjaro doses by more than 2.5 mg every four weeks. The maximum recommended dosage is 15 mg once weekly. Unlike Ozempic, Trulicity, or Victoza, Mounjaro is currently not approved for any heart-related uses. However, an ongoing clinical trial is assessing its effectiveness in reducing major adverse cardiovascular events in people with Type 2 diabetes. The study is anticipated to conclude in October 2024. Key Differences and Considerations The right GLP-1 agonist for you will likely come down to a few key factors like age, treatment goals, and underlying health conditions. Personal preferences like dosage frequency will also come into play. Dosing Frequency: Once weekly: Ozempic, Trulicity, Bydureon BCise, Mounjaro. Once daily: Rybelsus (oral), Victoza, Saxenda. Twice daily: Byetta. Administration Form: Injectable: All except Rybelsus (oral). Oral: Rybelsus. Indications: Type 2 Diabetes: All medications. Cardiovascular Benefits: Proven cardiovascular benefits: Ozempic, Trulicity, Victoza. Pediatric Use: Approved for children: Victoza (for children 10 years and older). Thanks again for listening to The Peptide Podcast. We love having you as part of our community. If you love this podcast, please share it with your friends and family on social media, and have a happy, healthy week! We're huge advocates of elevating your health game with nutrition, supplements, and vitamins. Whether it's a daily boost or targeted support, we trust and use Momentous products to supercharge our wellness journey.  Momentous only uses the highest-quality ingredients, and every single product is rigorously tested by independent third parties to ensure their products deliver on their promise to bring you the best supplements on the market. 

Send us a Text Message.https://ro.co/weight-loss/supply-trackerhttps://www.youtube.com/watch?v=mL_krAas70kNovo Nordisk Advertising:Novo Nordisk launches new advertising campaign "The Power of Wegovy"This advertisement includes the new indication for reduction of cardiovascular riskFor 2023, the #5 advertising spend for a drug was Rybelsus at $191 million.  The #6 advertising spend was Ozempic at $187.4 million (increase of 6% from 2022). More than 40% of the 2023 ad spend for Ozempic  went to online video platforms (i.e. social media like youtube)Link: https://www.youtube.com/watch?v=dhretLXYkZ4Structure Therapeutics GSBR-1290GSBR-1290 is a small molecule GLP-1 pillIn a 12-week phase 2 clinical study, a tablet formulation of GSBR-1290 had a weight-loss of 6.9%. This is comparable to Eli Lilly's phase 2 results for olforglipronAt Week 12, 67% of GSBR-1290 treated participants achieved ≥6% weight loss and 33% achieved ≥ 10% weight loss, compared to 0% for placeboAlso developing next generation combination GLP-1 candidates together with GIP, amylin, glucagon and apelin oral small moleculesLink (Madison Muller): https://www.bloomberg.com/news/articles/2024-06-03/structure-reports-early-oral-weight-loss-drug-data-adding-allureElon musk tweet:Elon Musk tweeted: Just make a lot of Ozempic/Mounjaro. It's not inherently expensive. The health benefits of reducing obesity far exceed the downside of GLP-1 inhibitors. We evolved under starving conditions and now make food that is plentiful and delicious. Whether that food is “processed” does matter, but is not a game changerThis tweet has currently been seen 325,500 timesShanghai Stem Cell Type 2 Diabetes Treatmenthttps://www.scmp.com/news/china/science/article/3263878/chinese-scientists-report-world-first-they-cure-patients-diabetes-cell-therapySupport the Show.MY WORK RELIES ON YOUR GENEROSITY, BECOME A MEMBER HERE:https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/joinVenmo: OnThePenCa$h App: ManOnMounjaroBECOME A MEMBER HERE:https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/joinSOCIAL LINKShttps://www.tiktok.com/@manonthemounjarohttps://twitter.com/ManOnMounjarohttps://instagram.com/manonthemounjarohttps://facebook.com/manonthemounjaro #Zepbound #releasethevials #mounjaro

YouTube Video Episode Available! Gulfcoast Ultrasound Institute YouTube Channel On this episode of The Sonography Lounge hosts Lori and Trisha sit down with Dr. Charlotte Derr & Dr. Allyson Hansen to discuss the GUARD Protocol (Gastric Ultrasound for Aspiration Risk Determination). With the increased use of GLP-1 Agonists (Semaglutide, with brand names such as Ozempic, Wegovy, Rybelsus, Etc) for both diabetes and weight loss, there has been an increased number of aspirations in patients undergoing procedures. One of the effects of GLP-1 agonists is delayed gastric emptying which keeps patients feeling "full" thus reducing the desire to eat and overall caloric intake and blood sugar variations. Typically 6-8 hours not eating is enough time for a patient about to undergo an elective procedure to digest and empty their stomachs thus reducing the risk of aspiration while under anesthesia. With patients on GLP-1 agonists, we are seeing gastric contents remaining for several days after the last meal which can increase the risk of aspiration.  Dr. Derr and Dr. Hansen, discuss how they are using ultrasound and the GUARD protocol to determine the volume of food in a patient's stomach before elective and emergency procedures. This quick and simple bedside technique can drastically alter a provider's pre-procedure course of action.  CHARLOTTE DERR, MD, RDMS, FPD-AEMUS, FACEP Dr. Derr is the Professor of Emergency Medicine and the Fellowship Director of the Advanced Emergency Medicine Ultrasound Fellowship Program at the University of South Florida Morsani College of Medicine in Tampa, FL and serves as the Co-Medical Director at Gulfcoast Ultrasound Institute. She is a fellow of the American College of Emergency Physicians and is a registered diagnostic medical sonographer. She has also obtained the Focused Practice Designation in Advanced Emergency Medicine US from the ABEM. She has authored and co-authored numerous articles, book chapters, and other publications on ultrasound and lectures throughout the US and internationally on diagnostic ultrasound.    ALLYSON HANSEN, DO Dr. Allyson Hansen is the Ultrasound Director at the University of South Florida Emergency Medicine program. She received her education at the University of South Florida and Campbell University. Dr. Hansen completed her Hackensack University Medical Center residency and Emergency Ultrasound Fellowship at Tampa General Hospital. She is passionate about teaching and is an instructor at Gulfcoast Ultrasound Institute. Gulfcoast Ultrasound Institute: GUARD Protocol Blog GUARD Protocol YouTube Hot Tip USF HEALTH: GUARD protocol blog   Upcoming POCUS Courses @ Gulfcoast Ultrasound Institute CME and Cross training resources: Gulfcoast Ultrasound Institute (Training materials and programs): www.gcus.com   Certification Agencies: American Board of Emergency Medicine (ABEM): https://www.abem.org/public Sonographer / Physician: American Registry of Diagnostic Medical Sonography (ARDMS): www.ardms.org Physicians: Alliance for Physician Certification & Advancement (APCA): www.APCA.org Point of Care Healthcare Providers: Point of Care Certification Academy (POCUS): www.pocus.org Sonographer / Physician: Cardiovascular Credentialing International (CCI): www.cci-online.org  Find an accredited long-term Ultrasound Program: https://www.caahep.org/Students/Find-a-Program.aspx    

Neste episódio, conto a minha opinião pessoal sobre as semaglutidas - substâncias presentes em alguns medicamentos, e que estimulam a produção de insulina no corpo - de um modo geral.Vou englobar tudo no mesmo "saco", então, falarei sobre os medicamentos Ozempic, Rybelsus, Wegovy, Monjauro e Tirzpartide por serem variações do mesmo tema.É bom? Para quem e quando? Descubra nesse episódio. Para mais informações sobre esse, e outros assuntos, acesse o meu site https://isabelafortes.com.br/. Para mais dicas, me siga no Instagram https://www.instagram.com/fortes_isabela. Produção: Wepod

Watch TV and you'll see Ozempic is presented as a “miracle drug” to help with weight loss. But it's important to slow down and ask more questions. In this episode of David v. Goliath, Matt Dolman and Stan Gipe welcome seasoned trial attorney Marcus Susen of Susen Law Group to the show. The conversation delves into the complexities of the Ozempic and Paragard lawsuits, highlighting Marcus's tenacity and his relentless pursuit for justice on behalf of affected patients. This discussion serves as a stark reminder of the importance of asking questions when it comes to health-related decisions.If you're interested in pursuing a case against Ozempic, Mounjaro, Wegovy, Rybelsus, and Trulicity, you can contact attorney Marcus Susen via email at marcus@susenlawgroup.com. Learn More and Connect☑️ Marcus Susen | LinkedIn ☑️ Susen Law Group | Facebook ☑️ Stan Gipe☑️ Matt Dolman | LinkedIn☑️ Dolman Law Group☑️ Dolman Law Group on LinkedIn, Facebook, Instagram, YouTube☑️ Subscribe: Apple Podcasts | Spotify | YouTubeThe insights and views presented in this podcast are for general information purposes only and should not be taken as legal advice for any individual case or situation. The information presented is not a substitute for consulting with an attorney. Nor does tuning in to this podcast constitute an attorney-client relationship of any kind. Any case result information provided on any portion of this podcast should not be understood as a promise of any particular result in a future case. Dolman Law Group Accident Injury Lawyers: Big firm results, small firm personal attention.

Send us a Text Message.1.7 mg of Wegovy is no longer in shortage:Semaglutide: FDA website updated to show 1.7 mg of Wegovy is no longer in shortageLink: https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Semaglutide%20Injection&st=cGNC introduces special section for GLP-1 users:GNC will have special section for GLP-1 users that will concentrate on four areas: GI Health, Retaining Lean muscle mass, Bone health, Nutritional supportLink: https://www.gnc.com/learn/newsroom/gnc-semaglutide-support-program.htmlIdentified upper dose values in tirzepatide high-dose trial20 mg and 25 mgPrimary Completion in this trial is 12/24/2024 (Merry Christmas) with final completion September 30, 2025 Link:  https://www.onthepen.com/post/higher-doses-of-zepbound-and-mounjaro-being-testedUS Senator Bernie Sanders investigating the price of Wegovy/OzempicOzempic costs $936 per month, while Wegovy costs $1,350Ozempic costs $155 in Canada, and cost $59 in Germany. This dramatic difference in cost has led to concerns about the accessibility and affordability of these drugs for American patients.With the cardiovascular disease indication, millions of additional medicare patients are eligible for taking Wegovy which means billions at the current prices Link:  https://www.onthepen.com/post/the-price-of-health-bernie-sanders-investigates-ozempic-and-wegovyLink: https://www.kff.org/medicare/issue-brief/a-new-use-for-wegovy-opens-the-door-to-medicare-coverage-for-millions-of-people-with-obesity/Germany is promoting their pharmaceuticals industry: tax breaks, and speeding up clinical trialsEli Lilly is investing 2.3 Billion Euros to build a glp-1 manufacturing plant in Germany:Link: https://uk.finance.yahoo.com/news/scholz-promises-support-pharma-sector-101833297.htmlLexaria begins phase 1 trial:Lexaria (stock symbol: LEXX) will test their technology to improve stomach absorption of Rybelsus in phase 1 trial (i.e. wouldn't need large 25/50 mg doses if absorption was better). They are also testing under tongue (sublingual) absorption of Rybelsus in another phase 1 trialLink: https://ir.lexariabioscience.com/news-events/press-releases/detail/246/lexaria-receives-ethics-review-board-approval-to-begin-newViking Therapeutics earnings callPlanning to start addition phase 2 trial of injectable VikingTide (VK2735) in Q4 of 2024 that will last 6-9 months (If you remember, the first phase 2 trial was only 13 weeks)The oral VikingTide (VK2735) phase 1 trial is still investigating higher and higher  doses due to the low side effect profile. They expect results in summer of 2024.MY WORK RELIES ON YOUR GENEROSITY, BECOME A MEMBER HERE:https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/joinVenmo: OnThePenCa$h App: ManOnMounjaroSOCIAL LINKShttps://www.tiktok.com/@manonthemounjarohttps://twitter.com/ManOnMounjarohttps://instagram.com/manonthemounjarohttps://facebook.com/manonthemounjaroThank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit my website at onthepen.com. You can also connect with me on social media, where I go by @manonthemounjaro (or @manonmounjaro on X). Let's continue this journey together towards a healthier and happier life!

Join renowned endocrinologist Gary Pepper, M.D. as he delves into the real-world experiences of individuals using Ozempic and Rybelsus for weight loss. In this exclusive interview with Ellen, hear her account of her experience with these potent medications.  With over 40 years of experience in the field, Dr. Pepper provides expert analysis and interpretation, offering invaluable insights for listeners considering similar treatments. Don't miss this opportunity to gain trustworthy information and stay informed about the latest developments in metabolic health. Keep watching for more from Dr. Pepper at his podcast Dr. Pepper...Really.  And don't forget to visit metabolism123 on YouTube and the website www. metabolism.com. Disclaimer: this podcast is for educational purposes only and is not intended to provide medical care or advice. Please consult with your own provider for your personal health care needs and concernsGary Pepper, M.D., a newly retired endocrinologist with 40 years of experience, brings clarity to numerous topics within the field of metabolic health. His view points are unhindered by corporate interests, unlike many other current "thought leaders" in medicine. Dr. Pepper, a dedicated educator, established his homebase website www.metabolism.com in 1996 and has blogged on important topics since then. Not one to be left behind by technology he began podcasting in 2020 with the onset of the pandemic and continues publishing vlogs on YouTube at his channel metabolism123. So whatever your choice in media, you will be gaining fresh insights by tuning in to his opinionated shows or reading his blogs on critical health topics.

Add another legend to the 2024 In Memoriam roll. And, another celeb whose behavior leaves us wishing we could forget them. She's Britney, bitch.  We think.  Her English isn't so good these days. Medicare shelled out $5.7 billion on Ozempic and other similar diabetes drugs in 2022, up from $57 million in 2018, according to a new KFF analysis. The pricey medications, which include Mounjaro and Rybelsus, have become super popular for the treatment of diabetes and for weight loss. But Medicare is not allowed by law to cover drugs for weight loss. Attention wiener enthusiasts: Do you have what it takes to get paid to measure 30 wieners (girth and length) across the country? BetUS is hiring a Wiener Connoisseur to travel to all 30 Major League Baseball stadiums in the country to find the biggest MLB wiener in all the land.

What's the best weight loss drug?Is semaglutide safe? What's the difference between Ozempic, Wegovy, and Mounjaro? If you are considering taking one of these new weight loss medications, then this episode is for you. These new “miracle” weight loss drugs are supposedly helping people lose weight like crazy.. Even Oprah recently announced that she was using them to help her lose weight! In this episode, we'll answer the following questions . . . What is semaglutide?What does it do in your body?Does it really help you lose weight? How much weight can you expect to lose from Ozempic or Wegovy? What are the semaglutide side effects?What I've learned from my people who have used it personally.And I'll share my two cents, just my opinion from everything I've seen, heard, and read. Please understand - I am not here to promote or demonize this drug. I just want to provide accurate information - the pros and cons, and then you can decide if this is something you might want to discuss with your doctor. What you do with your body and what you put into your body is 100% your business and your decision. I chose to do this episode, because I know that many of you consider me a trusted source of information in the health and weight loss world. That is a tremendous honor that I do NOT take lightly. So let's dig into this new weight loss drug called semaglutide or the commercial names that you might know - Ozempic, Wegovy, or Rybelsus. 1: JOIN THE INNER CIRCLE: support@CoreyLittleCoaching.com 2: PURCHASE RISE NUTRITION PRODUCTSWebsite: https://challenge2rise.com/Smart Energy: https://challenge2rise.com/product/smart-energy/Elite Omega-3 on Amazon: https://a.co/d/3dgilSGEssential Nutrients on Amazon: https://a.co/d/6rcULakElite Nutrients on Amazon: https://a.co/d/duQn1TDFREE MENOPAUSE DOWNLOAD: http://coreylittlecoaching.com/menopause

Semaglutide is a fantastic medication when used the right way. Anybody with a passing interest in weight loss has probably heard about semaglutide. Whether it's Ozempic, Wegovy, or Rybelsus, these antidiabetic medications have skyrocketed in popularity for the incredible weight loss results they can bring. There have even been shortages for the past couple of months! On the flip side, critics point out that around 85% of patients taking semaglutide gain most of the lost weight back if they stop cold turkey.  Semaglutide really works, and it can be life-changing for many people. But like anything else, there are always side effects and risks. In this episode, I'm giving you a down and dirty on semaglutide, why I've used it in my clinic, what you need to know before taking this medication, and more.   Highlights Why semaglutide is suddenly in the spotlight The development of semaglutide and how it works Comparing semaglutide with other weight loss interventions Why I recommend using semaglutide as one part of a broader change Common side effects and criticisms Patients and providers need a mindset shift when it comes to obesity It's critical to work with a qualified provider before starting these medications What you need to know about the most popular brands Considerations for getting semaglutide from a compounding pharmacy How 43 lbs snuck up on me over 20 years and how I turned it around Why I created H.E.R. University and how the program can support you   Mentioned in this episode Rocio Salas on Instagram @NewYorkEndocrinology https://www.instagram.com/newyorkendocrinology/   Sponsored by: Femmenessence It's a rare occurrence to find a non-prescription supplement that becomes a go-to for hormone health and Femmenessence is just that. Whether you're pre-menopausal, menopausal, or struggling with PMS, irregular periods, or other hormone imbalances, I highly recommend giving Femmenessence a try. Visit Femmenessence.com (https://femmenessence.com/) and use my code SHAWN20 for exclusive savings.   Needed Few things are as important in a woman's life as that journey to and through motherhood. There's so much that you can't control, but nutrition is a big one you can. Needed is a perinatal and women's health brand that I recommend to all my clients, whether they're in that perinatal stage or navigating perimenopause. Needed offers radically better nutrition products and education, backed by over 4000 practitioners. Visit ThisIsNeeded.com (https://thisisneeded.com/) and use my code DrT for 20% off your first month.   Resources Dr. Tassone's Practice https://www.drshawntassone.com/ The Hormone Balance Bible https://tassonemd.com/hormone-balance-bible/ Hormone Archetype Quiz https://tassonemd.lpages.co/hormonearchetypequiz/   Disclaimer This podcast and website represent the opinions of Dr. Shawn Tassone and his guests. The content here should not be taken as medical advice and is for informational purposes only. Because each person is so unique, please consult your health care professional for any medical questions.

Registered Dietician Kathleen Meehan joins me again for a conversation about the hot (and controversial) topic of semaglutide weight loss medications you know as Ozempic, Wegovy, and Rybelsus. We dive into the science of glucose, the often overlooked side effects and risks of these drugs, and the bombardment of marketing at every turn. Find Kathleen: KathleenMeehanRD.com Instagram.com/therdnutritionist Tiktok.com/@kathleenmrdn Don't forget to subscribe to this channel and get all the links you heard about on the show at realeverything.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

With drugs such as Ozempic and others becoming popular tools for weight loss, we wanted to review what the drugs are, what they do and give you information to help you and your clients navigate this new and challenging world. We are not medical professionals, but personal trainers and Pilates teachers are often the people clients will turn to for advice and we wanted you to be prepared for these conversations.

Semaglutdie-containing medications (like Ozempic, Wegovy, Rybelsus) have recently made headlines after some reports of gastroparesis. And experts don't know for sure if this side effect is linked to semaglutide itself.  Keep in mind that several other medications and health conditions can cause gastroparesis. There were no reports of gastroparesis in a 2-year clinical study of semaglutide use in patients with overweight or obesity. And while semaglutide and other GLP-1 agonists like tirzepatide (Mounjaro, Zepbound) and liraglutide (Victoza, Sexenda) cause stomach-related side effects like nausea, vomiting, upset stomach, diarrhea, and constipation, we know these effects happen because the medications slow down how quickly food leaves your stomach (delayed gastric emptying).  The good news is that these side effects are reported to be reduced after about 5 months (20 weeks) of use. In this podcast, we'll discuss gastroparesis, what causes gastroparesis, and how to lower your risk of gastroparesis. What is Gastroparesis? Gastroparesis occurs when the stomach muscles fail to function properly, leading to slowed or incomplete movement of food and liquid from the stomach to the small intestine, even though there isn't a blockage.  This delay can result in digestive issues and discomfort for individuals with gastroparesis. Symptoms include stomach pain, ulcers, and heartburn. You may also experience nausea and vomiting. What Causes Gastroparesis? One of the most common causes of gastroparesis is diabetes (T1DM or T2DM). High blood sugar levels over time can damage the vagus nerve, which controls the stomach muscles. Some individuals may develop gastroparesis as a complication of abdominal surgery, particularly those involving the stomach or intestines. Certain neurological conditions, such as Parkinson's disease and multiple sclerosis, can affect the nerves that control stomach function, leading to gastroparesis. It can also be caused by certain medications, including some opioid pain medications, antidepressants like venlafaxine, and allergy medications like diphenhydramine (Benadryl). It can also be caused by viral infections that can damage the stomach nerves and marijuana use. How can you lower your risk of gastroparesis? If you have diabetes, you can lower your risk by keeping good control of your blood sugar. You can also avoid medications that can cause gastroparesis. But it's important to know that 40% of gastroparesis cases are idiopathic (unknown reason). GLP-1 agonists and gastroparesis Research on semaglutide-induced gastroparesis is limited, but there have been patient reports of gastroparesis with GLP-1 agonists like tirzepatide, liraglutide, and semaglutide. However, the majority of the people who reported gastroparesis symptoms also had diabetes and their gastroparesis resolved after temporarily discontinuing the GLP-1 agonist. In some cases, diet changes (eating small frequent meals that are low in fiber and fat and avoiding carbonated beverages that may bloat the stomach) also helped resolve symptoms. Keep in mind: We mentioned earlier there were no reports of gastroparesis in a 2 year clinical study of semaglutide use in patients with overweight or obesity. The FDA states that they can't confirm if GLP-1 agonists directly cause gastroparesis or an underlying health condition. Remember: Gastroparesis symptoms are very similar to common semaglutide side effects. But just because these symptoms occur, it doesn't mean there's a problem. If your symptoms become severe, aren't going away, or worsen, you should let your healthcare provider know. They can help determine what steps you should take next. Thanks again for listening to The Peptide Podcast. We love having you as part of our community. If you love this podcast, please share it with your friends and family on social media, and have a happy, healthy week! We're huge advocates of elevating your health game with nutrition, supplements, and vitamins. Whether it's a daily boost or targeted support, we trust and use Momentous products to supercharge our wellness journey.  Momentous only uses the highest-quality ingredients, and every single product is rigorously tested by independent third parties to ensure their products deliver on their promise to bring you the best supplements on the market. 

When the road to wellness seems cluttered with obstacles, our latest Pound of Cure podcast shines a beacon of hope, revealing the twists and turns of obesity treatment advancements. We tackle Pfizer's paused study on the GLP-1 agonist, Danuglipron, due to its severe side effects, but also cast a promising  light on the horizon with Eli Lilly's Retatrutide and an upped dose of Novo Nordisk's Rybelsus. Understanding the quest for the right treatment is as personal as it is complex. We delve into the pharmaceutical industry's relentless pursuit to offer a spectrum of options that cater to individual needs and preferences.Amidst the science, we uncover the profound impact of bariatric surgery through the eyes of our guest, whose journey from pre-surgery apprehensions to post-operative triumphs embodies the transformational power of informed health decisions. The conversation extends beyond the operating room, exploring the vital role of education, dietary adjustments, and the indispensable support systems that provide a foundational pillar for sustainable weight management. This narrative isn't just about the scale's victory; it's a testament to reclaimed vitality and the unwavering human spirit.Rounding out our episode, we share actionable insights for those seeking to maintain a healthy weight and lifestyle. From simple strategies for meal planning to the economic landscape that shapes access to obesity treatments, we address the everyday challenges and victories on the path to wellness. We also respond to listener questions, reassuring one on the importance of health over numbers and highlighting that supplements like Creatine are just one piece of the muscle-building puzzle. Join us as we celebrate successes, advocate for accessible treatments, and provide a dose of motivation, leaving you equipped and inspired to navigate your own health journey.Pre-roll audio with updated disclaimer

See all the Healthcasts at https://www.biobalancehealth.com/healthcast-blog That is a strong statement, however I am confident in saying that belly fat can put you at risk for Alzheimer's disease, because it is a fact supported by medical research. These studies reveal that obesity, especially abdominal obesity (Beer belly, Gut, “Dunlap's disease”…..), increases the onset and rate of Alzheimer's dementia! Another reason to change your lifestyle to benefit your longevity. Abdominal obesity can come from fat accumulation right underneath your skin (the fat you can pinch between 2 fingers) OR the fat that grows inside your abdomen like an apron draped over the intestines. It is called “visceral fat”, and this type of fat is what places you in the crosshairs for several diseases of aging including Alzheimer's Disease, heart disease, stroke, diabetes, and rapid aging.  A large belly is more common in men, but it is still a risk for women if they develop an apple shaped body. Below is a picture of visceral fat, and a diagram of what it looks like in an artist's sketch of a normal weight person. When the yellow fat doubles and triples in thickness the abdomen pushes out to look like a “beer belly”.   Visceral fat extends from your stomach over the transverse colon and your small intestines like an apron.  This fat pad thickens with alcohol abuse (beer belly), high carbohydrate diet, overeating, junk food, under exercise and creates a large pad of fat that secretes inflammatory cells.  The resulting inflammation is the vehicle that damages your brain leading to Alzheimer's disease and damages your arteries leading to heart disease and stroke. In my office we use INBODY machines that measure your Visceral fat, BMI, and percent body fat.  Normal visceral fat is below #10 on our machine, BMI less than or equal to 25, and fat % for men < 19% and for women < 26%. The Research: A recent study correlated the size of patient's belly (visceral belly fat), and obesity with the amount of amyloid plaque (the cause of Alzheimer's disease) in their brain. This was measured by MRI in the study subjects' brains.  The age of the patients studied was between 40-60. The study found that the amount of visceral fat (fat inside your abdomen) is directly correlated with the amount of amyloid plaque and inflammation in the brain!  That causes Alzheimer's Disease. If that doesn't motivate you to lose your belly fat, then you are making a choice to eventually suffer from Alzheimer's disease, a heart attack, a stroke or arthritis.  If you are thinking that you will just wait for “something to happen”, then not making a decision to change your lifestyle is making a decision to take on illness in the future. We have new medications to help you lose that belly fat and they really work. You should ask your doctor to help you and if they don't understand the importance of arriving at ideal weight then look for a different doctor who will help you. Even with medication you will have to put in the work and self-control to turn down unhealthy foods when others are being unhealthy.  You will also have to add daily exercise to your schedule if you really want to avoid Alzheimer's Disease, heart attack, stroke and early death. The possible meds and habits that can help you lose your “belly”: ·     Limit calories and or carbohydrates ·     Increase daily exercise ·     Diet pills (amphetamines that older patients usually can't take) ·     Xenical (Orlistat)-Side effect is fatty diarrhea ·     Qsymia (topiramate/Phentermine) can increase BP ·     Contrave for craving (naltrexone/bupropion) can decrease sex-drive ·     Semelanotide (Imcivree-new), darkens the skin, expensive ·     Metformin ER an oral, effective medication to treat insulin resistance, and promote weight-loss ·     Victoza and Saxenda injections are diabetic treatments, that can cause GI reflux, however they work well for patients who have Type II Diabetes who need to lose weight. Even though many patients lost weight with these medications, many could not tolerate the drugs listed above because of the side effects.  These side effects limited our ability to help all patients lose weight…until now! Now, for the first time we have an effective way to help most people lose their dangerous visceral (belly fat). If you have a big belly you are at high risk for inflammatory diseases like Alzheimer's dementia, obesity, heart disease, diabetes, cancer and stroke. The new weight loss drug's generic name is Semaglutide, and has been marketed under several names: Wegovy, Ozempic, and Rybelsus. A second generic drug that is in the same family of drugs is called Tirzepetide, includes Mounjaro (for diabetics) and Zepbound (for weight loss). All of these drug's work for weight loss, pre-diabetes and Type 2 Diabetes.  Most insurance companies do not cover weight loss and they require a precertification for you to get the medication covered by insurance.  This precertification process is time consuming for the doctor and her staff, which costs the doctor an increase in her overhead to employ a nurse to provide this service for the patient. In general people with a BMI under 30 will not be covered for Semaglutide or Tirzapeptide, however if their BMI is over 30, there is a chance insurance will pay for one of these drugs for a period of time. The market price at the pharmacy is between $900/$1200 per month if you pay out of pocket to your pharmacy. Because of this fact and because we have so many patients whose pellets are not paid for by insurance, we provide access to the generic form of these drugs through a compounding pharmacy. The cost is a fraction of the normal out of pocket cost, about $560 for 3 months supply. In this way we have been able to treat many people who cannot afford to pay the exorbitant going rate for this medication. Because it is costly for a patient to receive the medication no matter how they are able to get it, It is very important for weight loss patients to be compliant and follow a low carbohydrate diet, exercise daily and to refrain from alcohol consumption while they are taking weight loss medications.  We require our patients who request these drugs to be seen at least every 2 months by one of our NPs or our weight loss specialist to help them get the best results possible. These drugs work for weight loss and diabetes by multitasking.  The ways the medication actually works are listed below: Semaglutide and Terzapeptide, ·      decrease hunger between meals   ·     you feel full faster than normal so you eat less ·     decrease sugar and alcohol-craving ·     decrease the release of sugar from the liver when you are fasting, which turns into fat ·     Prevent hypoglycemia which causes hunger and fat gain ·     Makes patients more insulin sensitive. Obesity is not just a lifestyle problem; it is a disease that should be treated with medicine PLUS lifestyle changes. These drug actions take place in the brain, stomach hormones, pancreas and liver, as well as in all the cells in your body. At Bio Balance Health® have years of experience in treating patients with bio-identical testosterone pellets and we have observed that weight loss plus testosterone pellets for patients over 40 allows patients to lose fat without losing muscle. Now we add these weight loss medications to T pellets, and we have the perfect combo for safe weight-loss (really fat loss). The biggest worry for patients is that they may not be able to get off this drug after they achieve ideal weight.  I have found that the longer you have been overweight and the more overweight you are, the higher the risk of needing maintenance medications to maintain your ideal weight. We try to wean our patients off injectable meds by switching them to Metformin ER, a drug that insurance will pay for. With these effective meds we finally, we have an effective preventive treatment to add to our testosterone and estradiol pellets for those people who view Alzheimer's as their worst nightmare, and for those patients who are worried about heart disease, diabetes and stroke  we can prevent the diseases that can ruin our “golden years”.   KCM Research: People with large amounts of visceral fat as they age may have higher risk of Alzheimer's disease. NBC News (11/20, Carroll) reports, “People who have large amounts of” visceral fat “as they age may be at higher risk of developing Alzheimer's disease, a new study suggests.” The findings were presented at the Radiological Society of North America's annual meeting. HealthDay (11/20, Thompson) reports that investigators “compared brain scans of 54 people between the ages of 40 and 60 with their levels of belly fat, BMI, obesity and insulin resistance.” The investigators “found that people who had more visceral fat compared with fat found just under their skin tended to have higher amyloid levels in the precuneus cortex.” The “relationship was worse in men than in women, and higher visceral fat measurements also were related to increased inflammation in the brain.”

Semaglutide, which is sold under the brand names Ozempic, Wegovy and Rybelsus, has become increasingly popular and is a medication you are likely to encounter in the clinical setting and when reviewing your patient's medical histories. In this article, you'll learn the key things to know about semaglutide using the Straight A Nursing DRRUGS framework. In this episode, you'll learn: The principles of the GLP-1 agonist drug class, including their main mechanism of action The two routes of administration The regular dose range for these medications What semaglutides are used to treat and why they work Key guidelines including administration, safety considerations, assessments, and drug-to-drug interactions The potential side effects, including a description of "Ozempic face" and what patients can do to lesson symptoms ___________________ Full Transcript - Read the article and view references FREE CLASS - If all you've heard are nursing school horror stories, then you need this class! Join me in this on-demand session where I dispel all those nursing school myths and show you that YES...you can thrive in nursing school without it taking over your life! Fast Pharmacology - Learn pharmacology concepts in 5 minutes or less in this audio based program. Perfect for on-the-go review! Pharmacology Success Pack - Want to get a head start on pharmacology? Download the FREE Pharmacology Success Pack

Are these new weight loss drugs that are on the market (and seem to be taking the world by storm) all that good for you?    A lot of celebrities and social media influencers are sharing their amazing results after taking weight loos drugs (like Ozempic). This got Dr. Jockers intrigued to learn more. And he's here today to share his findings!   How do these miracle weight loss drugs actually work? Dr. Jockers goes into the physiology as well as the side effects. Learn about how semaglutide medication can give you nausea and other digestive symptoms.    If you're taking this medication long-term, there are other side effects you seriously need to consider too! Make the best informed decision possible by learning from the best functional nutrionist around as Dr. Jockers proves a balanced view on semaglutide medications.    Please join us and please also share this information with someone you think may need it. Thank you.   In This Episode:   What is semaglutide? What is Wegovy and Rybelsus? What do glucagon-like peptide 1 (GLP-1) drugs actually do?  Understanding Advanced glycation end-products (AGEs)  How weight loss drugs increase satiety (leading to weight loss) What are the most common side effects? Understanding the potential of more damaging (rarer) side effects How can we improve our satiety level naturally?  Getting 30g of protein to increase your satiety Why a high protein, high healthy fat diet is the way to go Kick out toxins and boost your metabolism fast with the master of ALL antioxidants – GLUTATHIONE. When supplementing with high-quality glutathione… You will purge unhealthy toxins. You will lose weight with less effort. You will feel more energetic. You will notice a brighter complexion. And, you will feel much healthier overall!   But here's the thing, not all Glutathione supplements are created equal… If you're taking Glutathione in capsule or tablet form, you are missing out on key nutrients as they will simply pass through your body without being absorbed (you can thank your stomach acid for that).   However, my friends over at Purality Health have a NEW rapid-absorbing, delicious glutathione spray that delivers this powerful antioxidant straight to the areas of your body that need it most! Just pump a few sprays onto your tongue and watch as toxins naturally purge from your body.   The best part? You can experience these results in as little as 7 days. For a limited time, they are offering a special buy one get one free deal which is backed by a 180-day money-back guarantee. All you need to do is visit masterantioxidant.com/drj to access this exclusive deal.     Did you know that there's an entire line of teas specifically formulated to enhance the benefits of fasting? It's called Pique Tea and it's the highest quality tea that's out there! It's extracted via cold brew crystallization that gently preserves active compounds at their maximum potential, with no prep or brewing needed!   Pique Tea is also 100% organic and triple toxin screened for pesticides, heavy metals, and toxic mold (really common in tea). Pique Tea is designed to shut down your appetite, reduce cravings, enhance the benefits of fasting, and support healthy weight management.   Check out their range of Fasting teas, featuring Matcha, Cinnamon, Ginger, and Bergamot Fasting tea crystals. These teas are also organic, non-GMO, and gluten free!  For a limited time get up to 20% off plus two free gifts. Simply follow the link to piquelife.com/jockers to get 20% off your fasting teas!     “There's no miracle drug out there. So any drug you're gonna take is gonna have side effects." - Dr. Jockers.   Subscribe to the podcast on: Apple Podcast Stitcher Spotify PodBean  TuneIn Radio   Resources: piquelife.com/jockers - Get 20% off your fasting teas, plus two free gifts! Check out Glutathione Spray at masterantioxidant.com/drj - Backed by a 180-day money-back guarantee!   Connect with Dr. Jockers: Instagram – https://www.instagram.com/drjockers/ Facebook – https://www.facebook.com/DrDavidJockers YouTube – https://www.youtube.com/user/djockers Website – https://drjockers.com/ If you are interested in being a guest on the show, we would love to hear from you! Please contact us here! - https://drjockers.com/join-us-dr-jockers-functional-nutrition-podcast/  

John lists off all the things to be grateful for in 2023. Then, he interviews freelance writer for Fast Company - Adam Bluestein on the success of diabetes/weight loss drugs like Ozempic and Rybelsus. Then, year end calls from listeners: Steve in L.A., Laurie in Florida, Dave in Pittsburg, Rachel in L.A., and Stephen in Kentucky.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On episode 614 of the 40+ Fitness, we bring on the CEO of MD Exam and discuss the new weight loss drugs that have been the recent craze.  You can find the full show notes for this episode at 40plusfitnesspodcast.om/614. Ozempic, Wegovy, and Rybelsus (Semaglutide) Mounjaro (Tirzepatide)

Prepare yourself for a heavy dose of sarcasm on this episode of Vitality Radio as Jared takes a deep dive on the latest weight loss drug, Semaglutide - also known as Ozempic, Wegovy, and Rybelsus. You'll learn the history of this drug and just a few of its many side effects as well as the fate of many other weight loss drugs of the past. You'll also hear some tried and true alternatives for losing weight and reversing the damage that the standard American diet and environmental toxins have caused to our health, and our children's health.Products:Natural Factors WellBetX BerberineAdditional Information:Episode #227: VR Vintage: There is an Herbal Supplement that Works for Diabetes, Blood Pressure and Cholesterol Better than Drugs! Berberine is that Powerful!Visit the podcast website here: VitalityRadio.comYou can follow @vitalityradio and @vitalitynutritionbountiful on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Please also join us on the Dearly Discarded Podcast with Jared St. Clair.Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

Welcome back to our weekend Cabral HouseCall shows! This is where we answer our community's wellness, weight loss, and anti-aging questions to help people get back on track! Check out today's questions:    Alicja: Hi Dr. Cabral, I listen to your podcast daily and learn so much from you. I keep working on improving my health and see results. I'm going to put an infrared sauna to my house in a couple of months. It will be placed next to my office room and want to ask you if there is anything I could do or purchase to block EMFs from the sauna. Would Soma Vedic be helpful? Or maybe there are other things I'm not aware of? Thank you for all you do, you are such a big help and inspiration in my health rebuilding journey.   Alicja: Hi again :) I also have a question about coffee enema. What is your opinion about adding once capsule of clean gut probiotic to my coffee right before doing coffee enema? Would that be beneficial? I haven't tried this yet, but I'm very tempted. I take probiotics often, but my last stool test showed I don't have any Lactobacillius in my gut. Maybe trying to add it through coffee enema would be more effective? Thank you again. I appreciate your help so much.   Nadine: Hi Dr. Cabral, Thanks for the wealth of information you provide. I have suffered with severe gas and bloating for more than a decade. In January, 2022 I did an endoscopy which revealed I had H-pylori. After about 4 weeks of “heavy” antibiotics treatment I did a stool test which showed the H-pylori was gone but I was still very bloated and gasy. I then did a breath test and I tested positive for SIBO. I did another 2 weeks of antibiotics but I still suffer from bloating, gas and indigestion. I have not retested for SIBO as yet as my next appointment with my GI doctor is in March, 2023. I am always extremely tired, lots of fatigue, brain fog and generally feel like crap! Of note, I had thyroid cancer and my entire thyroid was removed in 2012. What do you recommend I do now?   Ann: Thank you so much for all you do Dr. Cabral. The guidance you give is truly life changing!! I have a question about some conflicting information and wonder if it just depends on my bioindividuality. I've read not to do heavy exercise (i.e. running) on an empty stomach, because it will spike cortisol, but also have seen that its better to wait to eat until 1 hour after a heavy workout for fat burning. I always start my day with a shake and I am more of a Vata or Pitta body type. I am currently in weight loss mode but also wonder if this advice changes when I go to weight maintenance. Just want to do what is healthiest for my body and longevity. Thank you again- you are truly changing so many lives:)   Anonymous: Hey Dr. Cabral , I hope you are having a beautiful day ! I have a quick question for you . What is your opinion on using a semaglutide for weight loss even though I'm not diabetic ? My Endocrinologist who is also a functional medicine Dr. Prescribed me Rybelsus in pill form to help aid my weight loss and insulin resistance. I have done the fatlosity program to a T. I'm afraid to try the semaglutide .. it seems it's the new fad weight loss pill or shot and I'm very weary of that . What is your opinion on the subject? I'm about 60 lbs overweight and it's extremely depressing . I eat pretty clean , work out & hardly drink any alcohol . I have done the big 5 and thyroid & hormones showed all normal .I'm Confused   Thank you for tuning into today's Cabral HouseCall and be sure to check back tomorrow where we answer more of our community's questions!    - - - Show Notes and Resources: StephenCabral.com/2612 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

This week, Jillian's crushing her latest healthy faves with recommendations ranging from podcasts to protein powders. Then we do a full run down on the newest weight loss drugs infiltrating Hollywood. Plus, listener questions on new workout trends, what foods to prioritize when eating on a budget, and more! For 25% off The Fitness App by Jillian Michaels, go to www.thefitnessapp.com/podcastdealFollow us on Instagram @JillianMichaels and @MartiniCindyJillian Michaels Community: https://www.facebook.com/groups/1880466198675549Email your questions to JillianPodcast@gmail.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.